PDF(Pubmed)
Abstract：
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor in the gastrointestinal tract and is most commonly seen in the stomach. The standard treatment for patients with advanced GISTs include both surgical resection and imatinib therapy. There have been cases that document the alterations of patients\' GIST histomorphology both with primary GIST prior to imatinib therapy and with recurrent GIST after imatinib therapy. However, there has been no documented case of a patient who has recurrent GIST with chondroid differentiation at the primary site after imatinib therapy. In this article, we report an incidental finding of a 58-year-old patient who had two treatments of imatinib therapy prior to surgical resection of her recurrent GIST in her stomach. We also explore through a mini-literature review the various cases of GIST with chondroid differentiation that have been reported to compare the histomorphology, immunophenotype, and patient demographic of these cases. This article is significant for reporting a rare finding of GIST after imatinib therapy and highlights the various presentations that GIST could acquire after imatinib therapy that exclude another malignant process, such as chondrosarcoma.
摘要：
胃肠道间质瘤（GIST）是胃肠道中最常见的间质瘤，最常见于胃部。晚期GIST患者的标准治疗包括手术切除和伊马替尼治疗。已有病例记录了伊马替尼治疗前原发性GIST和伊马替尼治疗后复发性GIST患者的组织形态学改变。然而,在伊马替尼治疗后,没有文献记载的一例患者原发部位GIST复发伴软骨样分化.在这篇文章中,我们报告了一名58岁患者的偶然发现,该患者在胃内复发性GIST手术切除前接受了两种伊马替尼治疗.我们还通过小型文献综述探讨了已报道的具有软骨样分化的GIST的各种病例，以比较组织形态学。免疫表型,以及这些病例的患者人口统计。这篇文章对于报道伊马替尼治疗后GIST的罕见发现具有重要意义，并强调了伊马替尼治疗后GIST可能获得的各种表现，这些表现排除了另一个恶性过程。如软骨肉瘤。
